Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Anthony R MatoLindsey E RoekerRyan JacobsBrian T HillNicole LamannaDanielle BranderMazyar ShadmanChaitra S UjjaniMaryam Sarraf YazdyGuilherme Fleury PeriniJavier A Pinilla-IbarzJacqueline BarrientosAlan P SkarbnikPallawi TorkaJeffrey J PuJohn N AllanSatyen GohilBita FakhriMichael ChoiCatherine C CoombsJoanna M RhodesPaul M BarrCraig A PortellHelen M ParryChristine A GarciaKate J WhitakerAllison M WinterAndrea SitlingerSirin KhajavianAriel F Grajales-CruzKrista M IsaacPratik ShahOthman Salim AkhtarRachael PocockKentson LamTimothy J VoorheesStephen J SchusterThomas D RodgersChristopher Paul FoxNicolás Martinez-CalleTalha MunirErica B BhavsarNeil BaileyJason C LeeHanna B WeissbrotChadi NabhanJulie M GoodfriendAmber C KingAndrew D ZelenetzColleen DorseyKayla BigelowBruce D ChesonToby Andrew EyrePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
For BTKi-naïve patients, selection of covalently binding BTKis results in high ORR and durable remissions. For BTKi-exposed patients, covalent BTK inhibition is not effective in the setting of BTKi resistance. PI3Kis following venetoclax do not appear to result in durable remissions. We conclude that BTKi in naïve or previously responsive patients and cellular therapies following venetoclax may be the most effective strategies.See related commentary by Rogers, p. 3501.